Navigation Links
Hepatitis C Phase 2A Trial Positive Results
Date:10/10/2011

SYDNEY, Oct. 10, 2011 /PRNewswire-Asia/ --

  • Phase 2a trial validates Biotron's novel drug
  • First-in-class new, oral drug
  • Good results on tolerability and efficacy
  • Full data to be presented to scientific conference in December

    • Australian drug development company Biotron Limited (ASX:BIT) has released headline results from its landmark Phase 2a trial of its lead drug candidate, BIT225 in Hepatitis C virus (HCV) infected patients.

    Preliminary analysis of trial data confirms that BIT225, an orally administered, small molecule drug, has good antiviral activity against HCV. Patients receiving BIT225 in combination with interferon and ribavirin (the current standard of care for treating HCV) had greater reductions in HCV levels than patients receiving standard of care treatment alone.

    Patients receiving the 400 mg dose of BIT225 showed the greatest levels of virus reduction, with an improvement of ~1 log (a measure of the amount of reduction of the virus in the blood of patients) over standard of care treatment at the completion of the dosing phase with BIT225. This is a significant improvement over and above the standard of care treatment in this patient group.

    Twenty four patients who had passed a stringent screening process were randomly assigned to receive either 400 mg or 200 mg BIT225, or placebo (ratio of 1:1:1), for the first 28 days of their standard treatment with interferon and ribavirin. The trial was undertaken at the Siriraj Hospital, Bangkok, Thailand. All patients were infected with genotype 1 HCV, which is the most common type of HCV and the most resistant to current treatment.

    Since the completion of the clinical phase of dosing with BIT225 in August, samples have been analysed and the resultant data has been subject to preliminary review by the independent D
    '/>"/>

    SOURCE Biotron
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3

    Related medicine technology :

    1. Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C
    2. Inovio Pharmaceuticals and VGX International to Advance Therapeutic Hepatitis C and Hepatitis B Synthetic Vaccines into Clinical Studies
    3. Lead Trial Attorney in Clark County Hepatitis C Trial, Robert Eglet, Asks Jury to Award $10 Million Compensatory Damages for Anne Arnold, $2.5 Million for James Arnold
    4. Updated Hepatitis C Practice Guidelines Now Available from AASLD
    5. PSI-938 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
    6. Mainor Eglet Attorney, Robert Eglet, Calls Teva Pharmaceuticals Vice President Craig Lea to the Stand in Hepatitis C Trial
    7. Second Trial in the Largest Hepatitis C Outbreak in U.S. Begins - Mainor Eglet Law Firm Files for Plaintiffs
    8. Hepatitis B Vaccine - Comprehensive Patent Search
    9. Pharmasset Announces the Expansion of the ELECTRON Trial in Chronic Hepatitis C
    10. FDA approves Incivek for hepatitis C
    11. FDA Approves Victrelis for Hepatitis C
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/17/2013)... , May 17, 2013  Sanofi (EURONEXT: SAN and ... pivotal study, JAKARTA , examining the ... primary endpoint in both dose groups. The primary endpoint ... spleen volume. Consistent with data reported in previous trials, ... and vomiting. Full results will be presented at an ...
    (Date:5/17/2013)... Sinovac Biotech Ltd. (Nasdaq: SVA ), a leading ... announced that it will release its unaudited financial results for ... Tuesday, May 28, 2013.  The Company will host a conference ... (May 28, 2013 at 8:00 p.m. China Standard Time) to ... recent corporate developments. To access the conference call, ...
    (Date:5/16/2013)... and ZURICH , May 17, ... Agency for Science, Technology and Research (A*STAR) and ... first healthy volunteer has been dosed in a Phase 1 ... Cytos, proprietary bacteriophage Qbeta virus-like particle (VLP) technology. In this ... this novel vaccine candidate and its potential to protect against ...
    Breaking Medicine Technology:Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6
    ... 2007 -- CytImmune, a,clinical stage nanomedicine company ... therapies has,been selected to present a poster abstract ... Meeting in Chicago Illinois,June 1-5. The poster session ... on June 3. Dr. Lawrence Tamarkin, CEO of ...
    ... in Journal of Cell Science Shows ONCONASE Uptake ... 05, 2007 /PRNewswire-FirstCall/ --,Alfacell Corporation today announced that ... follows to enter,cells. , Published in the Journal ... on studies conducted at the University of Girona ...
    Cached Medicine Technology:CytImmune To Present At ASCO Phase I Clinical Trial of CYT-6091 to,be Presented on June 3, 2007 2Researchers Identify Intracellular Pathway of Alfacell's Onconase 2Researchers Identify Intracellular Pathway of Alfacell's Onconase 3
    (Date:5/20/2013)... 20, 2013 The US Drug ... of a transvaginal mesh failure, we are now calling ... we have ever seen for women, and the damages ... a potentially huge number of US women. According to ... underwent procedures in which mesh was implanted vaginally to ...
    (Date:5/20/2013)... The Semi Truck Accident Victims Center ... service for an innocent victim of a catastrophic semi ... our services are unparalleled. What this means is if ... of a passenger vehicle involved in a semi truck ... Ohio, New Jersey, Indiana, Maryland, Georgia, Nebraska, Kansas, Michigan, ...
    (Date:5/20/2013)... Toronto, ON (PRWEB) May 20, 2013 ... hosted VoIP, Video, Data and IT Security solution ... video series aimed at providing business customers ... return of investments in BroadConnect services. With the ... product managers offer valuable insight into some of ...
    (Date:5/20/2013)... 20, 2013 On May 14th, premiere ... testimonial about how one of its patients originally came ... after being diagnosed with giant papillary conjunctivitis. “Giant papillary ... the eye, and for one of our patients in ... allergy,” says the Medical Director of the Atlanta Vision ...
    (Date:5/20/2013)... AlignLife of Waunakee is proud to announce ... the Tri-4-Schools children’s triathlon. Tri-4-Schools is a nonprofit organization ... kids active and fight childhood obesity. Their events aim ... nutrition, sportsmanship and self-confidence. Tri-4-Schools hopes to instill the ... and under so they can make healthy choices that ...
    Breaking Medicine News(10 mins):Health News:US Drug Watchdog Now Urges Transvaginal Mesh Failure Victims With Erosion To Call Them For The Names And Contacts Of The Best Women Attorneys 2Health News:Semi Truck Accident Victims Center Urges Family Members Of Victims Injured In A Horrific Semi Truck Accident In Any US State To Call Them First For An Unsurpassed Response 2Health News:BroadConnect’s Latest Video Solution Sets Aimed at Providing Technical Insights for Businesses Hoping to Gain Greater Returns from their Investment in Communication and Security Solutions 2Health News:Atlanta LASIK Practice Publishes a Patient’s Testimonial About Allergy to Contact Lenses 2
    ... replacement care, according to Dr. Xueya Cai and colleagues ... work, published online in Springer,s journal Clinical Orthopaedics and ... likely than Caucasians to receive total knee arthroplasty (or ... is widely performed in patients of all races with ...
    ... , TUESDAY, Sept. 13 (HealthDay News) --,Two decades after the ... abnormalities in their brains that in some cases have even ... part of a debilitating disorder known as Gulf War illness. ... to be caused by exposure to neurotoxins and nerve gas. ...
    ... study finds that infections following cardiac device implantations or ... in terms of patient mortality, even months after affected ... led to 4.8 to 7.7-fold increases in admission mortality, ... 4.0-fold increases in hospital length of stay, and 1.4 ...
    ... Chicago Many patients are responding to a new, ... out the bad cells. Atrial fibrillation (A-Fib) is one ... arrhythmia affecting Americans. However, new research shows that 70 ... with cryoballoon ablation, the freezing technique, are free of ...
    ... Steele HealthDay Reporter , MONDAY, Sept. 12 ... help people with mild memory problems or early Alzheimer,s ... small study suggests. But, the study authors added, ... therapy will actually benefit patients. Alzheimer,s disease, the ...
    ... WINSTON-SALEM, N.C. September 12, 2011 A year ... listening to doctor,s orders when it comes to taking ... of Wake Forest Baptist Medical Center shows. However, there ... "Medication non-compliance is a major risk factor for stroke ...
    Cached Medicine News:Health News:Does race dictate quality of care? 2Health News:Brain Blood Flow Abnormalities Persist in Gulf War Vets 2Health News:Costs, mortality skyrocket following infection in cardiac device recipients 2Health News:Freeze and desist: Disabling cardiac cells that can cause arrhythmia 2Health News:Insulin Spray May Improve Alzheimer's Symptoms 2Health News:Insulin Spray May Improve Alzheimer's Symptoms 3Health News:Researchers focus on secondary stroke prevention after study reveals room for improvement 2Health News:Researchers focus on secondary stroke prevention after study reveals room for improvement 3Health News:Researchers focus on secondary stroke prevention after study reveals room for improvement 4
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    Medicine Products: